GENEVA & BOSTON--(BUSINESS WIRE)-- Medimaps Group announced today that a novel method for improving osteoporotic fracture risk assessment, TBS iNsight®, is now available to clinicians in the United States through a partnership with Hologic, Inc. (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. Hologic is the global leader in the development and manufacture of Dual Energy X-Ray Absorptiometry (DXA) bone densitometry systems.
Medimaps Group – developers of the TBS iNsight® diagnostic tool – and Hologic, Inc. have reached an agreement to distribute TBS iNsight® in the United States and Canada leveraging Hologic’s extensive direct sales organization.
TBS iNsight® is a unique, easy-to-use software application that assesses bone texture - an index of bone microarchitecture – which in turn is expressed as the Trabecular Bone Score (TBS). The measurement is performed seamlessly using DXA images acquired from a bone mineral densitometry (BMD) scan. No additional patient scan time or radiation exposure is required and results are easily interpreted by physicians to enable them to better manage patients with high risk of fractures. TBS iNsight® has been cleared for marketing by the U.S. Food and Drug Administration.
Prof. Didier Hans, Chairman and Chief Executive Officer of Medimaps Group states; “It is well documented that 40-50% of osteoporotic fracture occurs in patients who are not determined to be osteoporotic by BMD alone, yet BMD remains the only diagnostic method available to most clinicians. A significant body of literature, including a recent study of over 29,000 women, has demonstrated that TBS, when combined with hip and/or spine BMD and FRAX® clinical factors, can help improve the prediction of future osteoporotic fracture risk in a clinically meaningful way. We’re very pleased to partner with Hologic to bring this valuable new predictive tool for better management of osteoporotic patients to the U.S. market.”
About Medimaps Group
Medimaps group – a Swiss company founded by a group of clinical practitioners and researchers - is a developer of innovative imaging software used in clinical practice for improved patient management with minimum impact on the workflow of the practitioner. The company has raised several rounds of venture capital to further commercialize TBS iNsight® in the osteoporosis treatment market and for product development of the TBS iNsight® tool for optimizing implant surgery in the dental and orthopedic markets.
Oscar Lazaro, +1-781-492-2012
Chief Commercial Officer
Source: Medimaps Group